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This review summarizes heme metabolism and focuses especially upon the control of hepatic heme
biosynthesis. Activity of 8-aminolevulinic acid synthetase, the first enzyme of heme biosynthesis, is of
primary importance in controlling the overall activity of this biosynthetic pathway. A-aminolevulinic acid
synthetase is subject to inhibition and repression by heme, and numerous basic and clinical studies support
the concept that there exists within hepatocytes a "regulatory" heme pool which controls activity of8-
aminolevulinic acid synthetase. In- addition, activity of this enzyme is repressed by feeding, especially by
ingestion of carbohydrates (the so-called "glucose effect"). Studies pertaining to the mechanisms underlying
this effect are also reviewed. The"glucose effect" appears to be mediated by glucose or perhaps by glucose-6-
phosphate or uridine diphosphate glucose, rather than by metabolites further removed from glucose itself.
Unlike the situation in E. coli, the "glucose effect" in liver ofhigher organisms is not mediated by alterations
in intracellular concentrations of cyclic AMP. Effects of heavy metals, especially iron, on hepatic heme
metabolism are also considered. Iron has been found to inhibit formation and utilization of uroporphy-
rinogen III and to lead to decreased concentrations ofmicrosomal heme and cytochrome P-450. Administra-
tion of large amounts of iron is also associated with an increase in activity of heme oxygenase, a property
shared by several other metal ions, most notably cobalt. This effect ofiron or cobalt administration is similar
to the effect of heme administration in increasing heme oxygenase activity; however, we believe it is unlikely
that iron, rather than heme itself, is a physiologic regulator of hepatic heme metabolism, although this
hypothesis has lately been proposed.
ABBREVIATIONS USED
AIA, allylisopropylacetamide
AIP, acute intermittent porphyria
ALA, 8-aminolevulinic acid
cAMP, 3',5'-cyclic adenosine monophosphate
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MDA, malonyldialdehyde
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INTRODUCTION
Virtually all cells in higher animals are capable of heme synthesis, either continu-
ally throughout life or at some stage of their development. The heme thus made
serves as the prosthetic group in a variety of proteins concerned with (i) the carriage
and transfer of oxygen within and among cells (e.g., hemoglobin, myoglobin); (ii) the
protection of cells against toxic oxidizing species (catalase, peroxidase); (iii) the
orderly and efficient transfer ofelectrons with attendant synthesis ofATP (mitochon-
drial cytochromes); and (iv) microsomal metabolism of fatty acids, steroids, and
xenobiotics (microsomal cytochromes). Quantitatively, developing erythrocytes
account for most of the heme produced by higher animals, but the liver is a second
major locus of heme synthesis. Furthermore, both inthe bone marrow and inliver an
increase in rate of heme synthesis is highly inducible: in bone marrow in response to
increased demand for circulating erythrocytes and in liver in response to inducers of
microsomal cytochrome P-450. Cytochrome P-450 is the terminal oxidase for
metabolism of numerous endogenous and exogenous compounds. This oxidative
metabolism produces polar products which are more readily conjugated and excreted
than are the parent compounds.
In recent years, however, it has also become clear that cytochrome P-450 and the
other components ofthe microsomal mixed-function oxidase system serve to activate
certain chemicals, producing proximate carcinogens and hepatotoxins from less
noxious precursors.
The primacy of bone marrow and liver as major sites of heme biosynthesis is
further exemplified by consideration of theporphyrias, a group ofdiseases in which
there exist inborn or acquired defects in heme biosynthesis. In these diseases various
heme precursors are over-produced in the bone marrow or the liver. The biochemical
bases for these diseases and the theoretical bases for their rational management can
be understood only if one understands the factors controlling normal heme biosyn-
thesis.
In this review, we shall focus only upon hepatic heme biosynthesis and its control.
In particular, we shall concentrate upon several clinically relevant factors which
influence activity of the enzyme 8-aminolevulinic acid synthetase, the rate-limiting
step of hepatic heme biosynthesis. These factors are(i) heme itself, the end-product
of the pathway, which can inhibit and repress 8-aminolevulinic acid synthetase; (ii)
iron which plays a promoting role in certain types of clinical and experimental
porphyria; and (iii) carbohydrate feeding which can repress the enzyme and amelior-
ate the porphyric state, an action termed the "glucose effect."
HEPATIC HEME BIOSYNTHESIS AND CATABOLISM
The steps in the pathway are outlined in Fig. 1.
In the first step, succinyl-CoA is condensed with glycine, forming the intermediate
ca-amino, 8-keto adipic acid which is probably decarboxylated to 8-aminolevulinic
acid (ALA) before being removed from the enzyme surface [1]. This reaction is
catalyzed by the mitochondrial enzyme ALA synthetase (E.C. 2.3.1.37). ALA leaves
the mitochondrion and in the cytoplasm, two molecules of ALA are condensed to
form porphobilinogen (PBG), the monopyrrole precursor of porphyrins. This
reaction (Fig. 1, step 2) is catalyzed by the enzyme ALA dehydratase(E.C. 4.2.1.24).
The intermediates formed from PBG which can give rise to protoporphyrin are not
themselves porphyrins but hexahydroporphyrins or porphyrinogens. The next step
requires two enzymes acting in concert (Fig. 1, enzymes 3 and 4) to condense four
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FIG. 1. Biosynthesis and Catabolism of Heme. The enzymes involved are identified by number 1. 8 -
aminolevulinic acid synthetase; 2. 8-aminolevulinic acid dehydratase; 3. Uroporphyrinogen synthetase; 4. Uropor-
phyrinogen III co-synthetase; 5. Uroporphyrinogen decarboxylase; 6. Coproporphyrinogen oxidase; 7. Protopor-
phyrinogen oxidase; 8. Heme synthetase; 9. Heme oxygenase; 10. Biliverdin reductase. Abbreviations: Ac, acetyl;
Pr, propionyl; Vi, vinyl.
molecules of PBG into one of uroporphyrinogen III. These two enzymes are
uroporphyrinogen synthetase (E.C. 4.3.1.8), also called PBG deaminase, and uropor-
phyrinogen III cosynthetase. Theformerenzyme actingalone catalyzes a head-to-tail
polymerization offour PBG rings toformuroporphyrinogen I, inwhich the"D" ring
has not been "flipped round" as it has been in uroporphyrinogen III. The cosynthe-
tase is a heat labile protein, which readily associates with the deaminase to form a
stable complex [2,3]. Recently it has been suggested that this complex first catalyzes
the formation of a dipyrrole, joined head-to-head, followed by two head-to-tail
additions, to form the physiologic heme intermediate uroporphyrinogen III [4].
However, the precise mechanism of this complicated reaction is not yet settled.
Activity of uroporphyrinogen synthetase is decreased in hemolysates [5-7], skin
fibroblasts [8,9] and livers [10,11] ofpatients with acute intermittent porphyria. This
genetically determined decrease is believed to be the primary defect in heme
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biosynthesis in this disease. A relative deficiency in uroporphyrinogen III cosynthe-
tase, compared to uroporphyrinogen I synthetase, occurs in congenital erythropoietic
uroporphyria [12]. The molecular basis for this imbalance is unknown.
The acetic acid side-chains of both the I and III isomers of uroporphyrinogen may
be sequentially decarboxylated, eventually to form the corresponding 4-carboxyl
coproporphyrinogen. These reactions are catalyzed by another cytoplasmic enzyme,
uroporphyrinogen decarboxylase (Fig. 1, enzyme 5) (E.C. 4.1.1.37). Activity of this
enzyme has been reported to be decreased in livers of patients with porphyria cutanea
tarda [13,14].
Coproporphyrinogen III then enters the mitochondrion where the enzyme copro-
porphyrinogen oxidase (E.C. 1.3.3.3) catalyzes oxidative decarboxylation of the
propionate side chains of rings A and B to vinyl groups, the product being
protoporphyrinogen IX (Fig. 1, enzyme 6). This enzyme has an absolute requirement
for molecular oxygen in animals [15] but not bacteria [16]. It cannot act on the I
isomer of coproporphyrinogen; thus in certain porphyric states uroporphyrinogen I
and coproporphyrinogen I, but never protoporphyrinogen I, are overproduced and
overexcreted. Activity of coproporphyrinogen oxidase has been found to be deficient
in leukocytes [17,18] and fibroblasts [19] of patients with hereditary coproporphyria.
This is believed to be the primary defect in this disease.
Protoporphyrinogen formerly was believed to be oxidized non-enzymatically to
protoporphyrin, a reaction which is rapid in the presence of oxygen. However,
preliminary studies suggested that this reaction is enzyme-catalyzed in mammalian
liver mitochondria [20,21] and chicken erythrocyte hemolysates [22]. More recently
firm evidence for an oxygen-dependent protoporphyrinogen oxidase (Fig. 1, enzyme
7) has been found in mitochondrial extracts from Saccharomyces cerevesiae [23] and
rat liver [24]. It seems likely that activity of this enzyme is deficient in the human
disease, porphyria variegata.
In a similar vein, although Fe+2 can be inserted into protoporphyrin non-
enzymatically at appreciable rates [25], the insertion is catalyzed enzymatically in
biological systems [26-28] by the enzyme heme synthetase or ferrochelatase (E.C.
4.99.1.1). Activity of this enzyme is deficient in liver [28], skin fibroblasts [28], and
erythroblasts [29] of patients with protoporphyria. The enzyme will also utilize Co+2
and Zn+2 and perhaps other divalent cations instead of Fe+2 as metal substrate.
Some of the heme synthesized by the liver undergoes rapid catabolism, contribut-
ing to "early labelled" bilirubin [29a], but most normally is incorporated in hepatic
hemoproteins, of which microsomal cytochrome P-450 quantitatively is most impor-
tant.
Hepatic heme may be catabolized in several ways. The major route normally
involves the microsomal enzyme heme oxygenase (Fig. 1, enzyme 9) (E.C. 1.14.99.3)
which requires molecular oxygen and NADPH-cytochrome P-450 reductase for
activity [30,31]. The final products of the reaction are iron, carbon monoxide (the
carbon deriving exclusively from the a-methene bridge of heme), and biliverdin-IXa.
Heme oxygenase can be induced by heme [32] and certain other substances [33-35].
The location and source of the heme which serves as substrate for heme oxygenase
is uncertain. Indirect evidence is compatible with the model proposed in Fig. 2.
In mammals but not birds, biliverdin IX is reduced to bilirubin IX a by a
cytoplasmic enzyme biliverdin reductase (E.C. 1.3.1.24). This enzyme can use either
NADPH or NADH as cofactor; only the IXa isomer is reduced, not the f,, y, or 8
isomers. Most of the bilirubin formed is then conjugated, the major products in most
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species studied being glucuronides formed by ester-linkages with the propionic acid
side chains of bilirubin [36].
CONTROL OF HEME BIOSYNTHESIS:
IMPORTANCE OF ALA SYNTHETASE
From the above summary of the heme biosynthetic pathway, it can be appreciated
that this process is quite complex. Likewise the regulation of heme synthesis is
complicated, and undoubtedly much remains to be learned about this regulation. A
detailed consideration of this regulation is beyond the scope ofthis paper. Instead we
shall focus on certain selected aspects of the problem in which we have been
particularly interested.
A major site for control of the hepatic heme biosynthetic pathway is at thelevel of
ALA formation [36-38]. And, despite the fact that ALA in mammalian liver may
give rise to [39] or arise from [40] Y, 8-dioxovaleric acid [39,40], most of the ALA
formed in animals, bacteria, and yeast undoubtedly is synthesized by ALA synthe-
tase. Our previous inability to detect ALA formation froma-ketoglutarate in rat liver
homogenate via direct reduction ofa-ketoglutarate to Y, 8-dioxovalerate [41] is in
accordance with the notion that ALA synthetase is required. This is also consonant
with the general biochemical principle that the first enzyme in an unbranched
biosynthetic pathway exerts a key "gating function" in controlling the flux of
substrate down the pathway. ALA synthetase may be considered the rate-controlling
enzyme of heme biosynthesis in most circumstances. However, if activity of ALA
synthetase is markedly increased, as occurs in certain types ofclinical orexperimental
porphyria, then other enzymes in the pathway may become rate-limiting, and
accumulation ofintermediates may occur proximal to these. Indeed inthe hereditary
hepatic porphyrias, exactly these phenomena appear to occur. As summarized above,
the decreased activity of various enzymes of the pathway is genetically determined in
these diseases. Under such conditions, the pattern of heme precursor accumulation
will vary, depending upon the kinetic parameters (K M, Vmax) of the enzymes and
their substrate concentrations. (See Tschudy and Bonkowsky[42] for a mathematical
model of a simplified multi-step pathway of this type.)
Regulatory Heme and Control ofALA Formation
One theory which has proved very useful in considering the control of hepatic
heme biosynthesis is that the activity of ALA synthetase, and hence of the entire
pathway, is under negative-feedback, end-product control, as shown in Fig. 2. It is
hypothesized that there exists a "regulatory" or "repressor" heme pool which tightly
controls ALA synthetase activity [36-38,43]. Furthermore, as shown in Fig. 2, this
pool may be envisioned as exchangeable (and in dynamic equilibrium) with heme in
the liver cells' numerous hemoproteins.
Lascelles and her co-workers, studying Rhodopseudomonas spheroides, first
obtained evidence that heme could both inhibit the activity and repress the synthesis
of ALA synthetase [26].
Regulatory Heme and Experimental Porphyria
Major further advances were made possible by the discovery that certain porphy-
rinogenic chemicals increased markedly the activity of ALA synthetase, apparently
by inducing new enzyme synthesis [44]. Evidence from studies with chick embryo
liver cells [43] and rat liver [45-57] indicated that inducing drugs stimulated new
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FIG. 2. Summary of Control of Hepatic Heme Metabolism and Compartmentalization of Hemoproteins. A
mitochondrion is shown in the center of the figure, draped with protein-synthesizing rough endoplasmic reticulum
(RER) to the left and smooth endoplasmic reticulum (SER) to the right. The heaviness ofthe arrows from mitochondrial
heme to other pools roughly indicates the importance of the pathway in rat liver.
Minus signs indicate repression or inhibition; plus signs, induction or activation. Other abbreviations: AIA,
allylisopropylacetamide; ALA, 8-aminolevulinic acid; b5, cytochrome b5; CO, carbon monoxide; Coprogen, copropor-
phyrinogen III; P-450, cytochrome P-450; PBG, porphobilinogen; Proto, protoporphyrin IXa; Px, peroxisome; ROH,
hydroxy fatty acids, final products oflipid peroxidation; ROOH, lipid hydroperoxides; SuccCoA, succinyl-CoA; TPO,
tryptophan pyrrolase; Uro'gen, uroporphyrinogen 111.
enzyme formation, a point now firmly established for chick cells, by use of
immunological techniques [48].
Heme was found to prevent or reverse these inducing effects [48]; it is unclear
whether heme acts at the level of translation [49] or transcription [50]. In the intact
rat, intravenous heme has rapidly decreased ALA synthetase activity [51].
Further experimental evidence for the existence ofa regulatory heme pool is that a
number of potent, porphyrinogenic compounds, which upset the normal control of
heme biosynthesis and induce excess production ofALA, PBG, and porphyrins, may
be envisioned to reduce the size of the regulatory heme pool [36,52]. For example,
allylisopropylacetamide (AIA) degrades liver heme to porphyrin-like "green pig-
ments" (not biliverdin), rapidly decreasing total hepatic heme and microsomal heme.
It produces marked increases in ALA synthetase activity and heme precursor
accumulation. In contrast, its congener propylisopropylacetamide (PIA), which does
not accelerate heme degradation, while a potent inducer ofcytochrome P-450, is only
a weak inducer of ALA synthetase [53].
The porphyrinogenic compounds 3,5-diethoxycarbonyl-1,4-dihydrocollidine
(DDC) and griseofulvin have been found to inhibit heme synthetase, particularly in
mice [53]. It has been proposed that this inhibition is sufficient to deplete the
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regulatory heme pool and increase ALA formation. Thus the protoporphyrin
accumulation characteristically seen in such mice may be due both to a decrease in
the efficiency of its utilization and a secondary increase in synthesis. Other actions of
the drug remain quite possible, however, since Anderson [53a], Rifkin [53b], and
Sinclair et al. (unpublished observations) have found in the chick embryo, the
organism in which ALA synthetase is most inducible by DDC, that (i) even 95
percent inhibition of heme synthetase by low doses of DDC does not lead to ALA
synthetase induction and (ii) there is no decrease in cytochrome P-450 following
DDC administration in amounts which produce marked protoporphyrin accumula-
tion. These results raise questions about the notion that the DDC effect in inducing
ALA synthetase relates solely to inhibition of heme synthesis. On the basis ofthis and
certain other evidence, we favor the view that ALA synthetase induction occurs by
other mechanisms as well.
A final point of interest is that when two compounds which affect heme metabo-
lism in different ways are given together, a "synergistic' effect is observed [53-55].
That is, the induction ofALA synthetase is much greaterthan with either alone and is
also greater than simply the additive effects of the two separately. An apparent
example of this kind of effect is discussed below in the section on Iron and the
Regulation of Hepatic Heme Metabolism.
Regulatory Heme and Clinical Porphyria
The human disease, acute intermittent porphyria (AIP), provides a clinical parallel
to these ideas. As mentioned above, in this disease there is a genetically determined
decrease in activity ofuroporphyrinogen synthetase (Fig. 1, enzyme 3). Some persons
with this defect do not overproduce ALA or PBG, whereas others do. All, however,
are probably uniquely sensitive to drugs which induce cytochrome P-450. Drugs such
as phenobarbital or phenytoin are well known to exacerbate or first make manifest
the biochemical and clinical features ofAIP [37,38]. The increase in ALA production
may result from a synergism between the genetically determined partial deficiency in
heme production and the drug-induced increase in heme utilization for cytochrome
P450. These two effects, acting synergistically, may be envisioned to deplete the
regulatory heme pool and secondarily to increase ALA formation.
We first obtained convincing evidence for the existence of heme regulation of
human ALA formation when we demonstrated that heme, given intravenously to a
patient with AIP, promptly and dramatically diminished her ALA and PBG
overproduction [56, Fig. 3]. This phenomenon has since been reproduced by others
[57-60] in nearly all patients thus far treated. In some patients, heme therapy has also
been of striking clinical benefit, and in none has it made patients worse, although a
large dose led to transient oliguria in one [58]. Furthermore, heme therapy has also
been effective in apparently reversing the heme precursor overproduction in variegate
porphyria [58], congenital erythropoietic uroporphyria [58], and protoporphyria
[51]. In the latter two conditions, porphyrin overproduction arises from erythroid
cells, suggesting that the heme effect is not limited to the liver, although a different
interpretation was offered by the authors of the abstract on protoporphyria. These
results support the concept of heme regulation of ALA synthesis and negative-
feedback control of heme synthesis by the end-product, in man as in lower animals
and bacteria. They also establish a new and possibly life-saving treatment for
porphyria.
However, further pharmaceutical development and pharmacological testing
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FIG. 3. First Demonstration of Heme Repression of Hepatic ALA Synthetase Activity in Man. Effect of
Intravenous Heme on Serum Concentrations of 8-aminolevulinic acid (ALA) and porphobilinogen (PBG) in a patient
with acute intermittent porphyria. (Redrawn from [56]).
should be done. For example, the minimal effective heme dose and the optimal
therapeutic regimen have not been established. An oral heme preparation, which can
be absorbed by the gut and enter hepatocytes and other cells, would be highly
desirable. Unfortunately, thus far we have been unable to interest pharmaceutical
companies in producing heme or intrying to develop such an oral preparation. Heme
itself is not patentable, and perhaps special formulations would not be profitable.
Regardless of this, we believe that heme for human use should be produced as a
service to those patients whose well-being or very lives may depend upon it.
In summary, there is now overwhelming clinical and experimental evidence that
the heme biosynthetic pathway is subject to end-product negative feedback control,
operating primarily at the level of ALA synthetase. The major effect ofrelatively low
endogenous heme concentrations in decreasing activity ofthe enzyme is probably by
repression of enzyme synthesis. The purified enzyme activity is also inhibited by
somewhat higher concentrations [62,62a]. Since, as shown in Fig. 2, heme is
synthesized in the mitochondrion which is the sub-cellular location of ALA synthe-
tase, the "local" concentration of heme may be sufficient to inhibit the enzyme
activity directly under physiological conditions.
IRON AND THE REGULATION OF HEPATIC HEME METABOLISM
Iron Lack
As mentioned in the first section, in animals, ferrous iron is the physiological metal
substrate for the final enzyme of the heme biosynthetic pathway. Therefore an
adequate supply of iron is necessary for normal heme synthesis. Anemia is often due
to iron lack, and in such states erythrocyte protoporphyrin levels are increased, as
expected. In contrast, although extensive studies have not been done, we are unaware
of evidence that hepatic heme synthetase activity is deficient in animals with iron
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lack. Indeed, such animals have increased levels of oxidative demethylation of
aminopyrine and hexobarbital [63], activities dependent upon the hemoprotein
cytochrome P-450. Cytochrome P-450 levels were not affected by iron lack [63,64].
This difference in sensitivity of bone marrow and liver to iron lack probably relates
to the fact that the liver's iron requirement is considerably less than the bone
marrow's. Also hepatocytes recycle their iron efficiently, since their hemoproteins
never leave these cells, whereas erythrocytes are constantly leaving the bone marrow,
eventually to be destroyed largely at distant sites of reticulo-endothelial activity.
Iron Overload and Porphyria Cutanea Tarda
In contrast, iron excess does affect hepatic heme metabolism. An early observation
in this regard was that patients with porphyria cutanea tarda(PCT) commonly had
hepatic siderosis and that the porphyric state was ameliorated by iron removal
[37,38,65,66]. Iron overload may be considered a promoting or potentiating factor in
pathogenesis of this type of porphyria. Other factors, however, are clearly important
in pathogenesis since, on the one hand, most patients with severe hemosiderosis or
hemochromatosis do not have overt porphyria; and on the other a toxic porphyria
resembling PCT may be produced in animals or man without hepatic siderosis.
Hepatic Iron and ALA Synthetase
It has long been recognized that many patients with PCT have hepatic fibrosis or
cirrhosis, as well as an increase in hepatic iron deposition. Many ofthese patients also
imbibe ethanol heavily. In addition, cirrhotic patients without overt PCT commonly
exhibit excess porphyrinuria, excreting increased amounts of uro- and copropor-
phyrins, particularly the former [37,67,68]. Cirrhotics, especially those with large
porto-systemic shunts, also tend to have hemosiderosis [69]. The question therefore
arose whether disturbances of porphyrin metabolism in cirrhotic subjects resulted
from hepatic iron deposition or from other causes.
To answer this question and to learn more about control of human hepatic ALA
synthetase activity, we measured ALA synthetase activities in twelve cirrhotic
subjects and in 16 controls who had a similar degree of hepatic fat and inflammation,
but without cirrhosis [68]. Activity of the enzyme, when assayed optimally, in the
presence of an exogenous system for succinyl-CoA generation, was significantly (p<
0.005) increased in homogenates of cirrhotic livers (1297 ± 664 pmol ALA h-' mg-,
protein) vs. the controls (548 ± 252 [mean ± 1 SD]).
In the controls in this study, as shown in Fig. 4, activity of hepatic ALA synthetase
was correlated positively (P = 0.04), albeit weakly, with hepatic iron concentration. In
homogenates from cirrhotic livers, the activity of ALA synthetase also tended to be
higher in subjects with more liver iron, but the correlation was even less close,
suggesting that other factors are more important in this group [68]. (It is of interest
that ethanol ingestion could not be incriminated as such a factor, despite the fact that
larger doses of ethanol modestly and briefly induce rat liver ALA synthetase [70].)
These studies suggest that, even in subjects with no overt abnormality in porphyrin
metabolism, hepatic iron status affects the heme synthetic pathway. They are
corroborated by the recent report that activity of hepatic ALA synthetase is increased
in rats loaded over six weeks with iron-dextran [71].
The effects of acute, high-dose iron administration on rat liver ALA synthetase
have been studied more extensively. Stein et al. first demonstrated a striking
"synergism" or potentiation between AIA and ferric citrate on induction of hepatic
ALA synthetase in rats [72,73]. The increase was not due to enzyme activation nor to
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FIG. 4. Human Hepatic ALA Synthetase vs. Hepatic Iron Concentration in Subjects Without Cirrhosis. Redrawn
with permission from [68].
The regression equation is Y = 3.87 x + 426, r = 0.53, P = 0.04.
alteration in enzyme half-life, and indirect evidence was obtained for increased
mRNA synthesis in mediating the induction [73]. We have confirmed this synergistic
effect in rats (Fig. 5) and, in preliminary studies with chick embryo liver cells in
culture, a similar modest effect has been observed.
While the molecular basis for this effect is unknown, recent studies have suggested
several possible explanations. In considering these, it is convenient to refer to Fig. 6,
which summarizes known and possible iron effects on hepatic heme metabolism. Site
1 represents the role of iron as substrate for heme synthetase.
Site 3 represents a role for iron in inhibiting uroporphyrinogen decarboxylase
(Uro-D, cf. Fig. 1, step 5), first demonstrated in cytoplasmic extracts of pig liver by
Kushner et al. [74]. Incubation for 2h at 37°C with 0.7 mM ferrous iron decreased
Uro-D by up to 40 percent. They concluded that these studies were relevant to the
pathogenesis of PCT, in view oftheiron excess common inthis disease and in view of
the fact that porphyrins containing five to eight carboxyl groups are the major
products over-produced and over-excreted in PCT.
In other studies of similar design, iron inhibition of uroporphyrinogen III
cosynthetase had also been observed [75]. Nevertheless, it was unclear that these
studies in vitro with inorganic iron salts provided an entirely adequate model for
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PCT in which the hepatic iron, chronically accumulated, is presumably stored in
ferritin and hemosiderin.
Subsequently, activity of Uro-D was found to be decreased in liver extracts and
hemolysates of patients with PCT [13,76]. However, activity in the liver did not
IRON EFFECTS ON HEPATIC HEME METABOLISM
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increase after iron removal and clinical remission of disease [13]. This failure to
observe an increase in enzyme activity may relate to the fact that the cytosolic liver
extract used as the enzyme source is diluted 25-fold for the assay. The dilution may
decrease the iron concentration too low to be inhibitory in the assay. If this
explanation is correct, then the finding of decreased Uro-D activity in extracts from
PCT patients, compared with controls, is evidence for a genetically determined
decrease in enzyme activity (see below). It also suggests that addition of iron to the
assay mixture might be expected to inhibit activity ofthe enzyme both from normal
human and PCT liver.
Kushner et al. have also found that Uro-D activity is decreased in hemolysates
from relatives ofPCT patients [13] who clinically are unaffected and who presumably
have no iron overload. However, this finding of decreased erythrocyte enzyme
activity in PCT patients or their relatives has not been confirmed by Elder, studying
other kindreds with a different Uro-D assay [14]. Currently, it is unclear whether
these differences are attributable to the different assays or to the different patients
studied; an answer to this question should not be difficult to achieve, requiring only
that both assays be run on the same hemolysates. The differing results can be
reconciled by the existence oftwo forms of PCT, a genetic and an acquired sporadic
form. Kushner et al. appear to have studied kindreds with the former, whereas Elder
et al. studied patients with the latter.
In any case, while direct iron inhibition ofUro-D may contribute to the pathogene-
sis of PCT, the possibility that iron acts in other ways in this disease should not be
discarded [77].
Iron and Stimulation ofLipid Peroxidation and Heme Oxygenase
An alternative site for iron action in heme metabolism results from the ability of
iron to stimulate lipid peroxidation (Fig. 6, Site 4). This effect was originally
described in vitro in mitochondrial preparations, incubated with ferrous salts
(0.05-0.3 mM) and ascorbate (0.3-2.0 mM) [78,79]. It was found that mitochondrial
swelling, dysfunction, and eventual disruption occurred [79]. Later, iron was found
to stimulate NADPH- and enzyme-dependent microsomal lipid peroxidation in
vitro, with accompanying losses of heme and cytochrome P-450[80-83]. Hrycay and
O'Brien have proposed that this loss ofcytochrome P-450 heme is due to its action as
a lipid peroxidase, during which the heme is degraded [84], as suggested in Fig. 6.
Experiments ofthis type have led to the suggestion that toxic effects ofiron overload
in vivo are secondary to enhancement of lipid peroxidation; however, evidence for
this has proved elusive.
Nevertheless, a large single dose of iron-dextran (100 mg Fe/kg) was found 24
hours later to decrease microsomal cytochrome P-450 concentration in ratliver by 35
percent and to increase ALA synthetase activity 3.4-fold [82]. Lipid peroxidation in
vivo was not examined in these experiments.
Recently a single parenteral injection of a large dose of iron [34,34a] or certain
other heavy metals [34] has been observed to lead to an increase in rat hepatic heme
oxygenase activity (Fig. 6, Site 5). It is interesting that this activity has several
similarities to the hemedegradation reaction associated withlipid peroxidation: both
utilize NADPH, 02, and native microsomal protein ("enzyme"); both are activated
by fasting; and both produce carbon monoxide and green heme degradation
products, biliverdin IXa in the case ofheme oxygenase and uncharacterized products
in the case of the reaction associated with lipid peroxidation. These latter products
may include a mixture of biliverdin isomers.
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FIG. 7. Chronic Iron Overload and Hepatic Microsomal Heme and Hemoprotein Concentrations in the Rat.
250-350 g male Wistar rats received three 1 ml doses of iron-dextran (50 mg/iron/rat, IP) on alternate days and were
killed on the eighth day. Other rats received repeated I ml doses offerric citrate(85-120 smol IP), five times per week for
9 weeks. Controls received appropriate amounts of dextran-40 or sodium citrate, as shown. Other controls for the iron-
dextran experiment received three I ml doses of 0. 15 M NaCl; microsomes from these saline-treated controls had total
heme concentration = 1.7 ± 0.27 and cytochrome P450 concentration = 0.8 ± 0.09 nmol/mg protein. The latter value is
significantly less than that for microsomes from rats receiving dextran-40 (p < .05). (Data redrawn by permission from
[128].)
As shown in Fig. 7, we have found that decreases in rat hepatic microsomal
cytochrome P-450 and heme were even greater with repeated administration of iron
dextran than with a single dose. Cytochrome b5 concentrations also fell, although to
a lesser degree. Furthermore, as shown, similar effects were observed when compar-
able iron overload was achieved by chronic injections offerric citrate. It is uncertain
whether these changes occur in relation to increased lipid peroxidation as well as
increased activity of heme oxygenase [71]. Whether these changes are associated with
decreased rates of mixed function oxidase activity in vivo and whether similar
changes occur in patients with hemosiderosis or hemochromatosis are other impor-
tant unanswered questions. It is also unknown whether these decreases in microsomal
heme and hemoproteins are associated with decreased rates ofhepatic hemesynthesis
(e.g., secondarily to a block in uroporphyrinogen III production or utilization as
discussed above).
Regardless of whether hepatic iron excess stimulates heme catabolism due to
increased lipid peroxidation or heme oxygenase, the net effect on hepatic heme
homeostasis and ALA synthetase would be similar. But these effects on heme
degradation are different from those due to iron inhibition of heme synthesis.
Studies on Acute Iron Potentiation ofALA Synthetase Induction
Currently, we are studying the mechanism whereby a single dose offerric citrate,
enterally administered, exerts a synergistic effect on AIA-mediated induction of rat
hepatic ALA synthetase. To our surprise, despite the results just described for
chronic iron overload, in our initial studies of acute ferric citrate administration, we
failed to obtain evidence either that iron inhibited Uro-D or decreased microsomal
cytochrome P-450 concentrations.
In these experiments 125-150 g female Sprague-Dawley rats were fasted for 24 h
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TABLE I
Activity of Uroporphyrinogen Decarboxylase (Uro-D) and Concentrations of Cytochrome P450 in
Livers of Rats Treated with Ferric Citrate and AIA
Microsomal
Cytochrome
Treatment Uro-D P450
Gavage SC (Units/mg protein) (nmol/mg protein)
Sodium Citrate + NaCI 1.86 f 0.08 0.99 * 0.003
(Control) range 1.65 - 2.02 (n = 4)
Ferric Citrate + NaCI - 1.00 ± 0.007
(Iron only)
Sodium Citrate + AIA 2.1, 2.2 0.72* 0.008
(AIA only)
Fe Citrate + AIA 1.8, 1.7 0.71 * 0.005
(Combination)
Female Sprague-Dawley rats (125-150g), fasted for 24 h, were treated as shown and sacrificed 17 h later.
Uro-D assays were kindly performed by Dr. Jas. Kushner, using his standard assay[75]. Microsomal Cytochrome
P.450 determinations were performed by the method ofOmura and Sato[125] and proteins bythemethod ofLowry
et al. [126], modified in that microsomes were incubated 10 min with deoxycholate (0.5%) prior to assay.
and then treated with ferric citrate (700 mg/kg by gavage), AIA (400 mg/kg S.C.
dissolved in 0.15 M NaCi), or the combination. Controls received sodium citrate and
0.15 M NaCl. As listed in Table 1, ferric citrate treatment alone had no effect on
cytochrome P-450 concentrations nor on Uro-D activity. AIA treatment had slight, if
any, effect on Uro-D, although it led to a significant decrease in microsomal
cytochrome P-450 concentrations as expected. Effect of the combination treatment
on these parameters was not different from AIA alone.
Furthermore, no iron effect on lipid peroxidation in vivo was found. Lipid
peroxidation was assessed by measurement of malonyldialdehyde (MDA). Treat-
ment with ferric citrate or AIA alone did not increase endogenous hepatic MDA
concentrations (Fig. 8). However MDA concentrations were moderately increased in
livers of rats treated with AIA and ferric citrate 17 h before sacrifice.
In these experiments, hepatic iron concentrations in rats given ferric citrate were
increased by 40-50 percent above controls and iron potentiation of ALA synthetase
(cf. Fig. 5) induction by AIA was demonstrated. Therefore, our failure to observe an
effect offerric citrate alone, either upon liver MDA or cytochrome P450 concentra-
tion, cannot be attributed to the iron not entering the liver or not exerting a
metabolic effect.
These preliminary results do suggest that 17 h after administration offerric citrate
and AIA to rats, their livers contained increased amounts of MDA, a product oflipid
peroxidation. However, the concentration of microsomal cytochrome P-450 was not
lower than in livers of rats given AIA alone.
In interpreting these results, several points should be kept in mind:
1. Our measurements in vitro may not provide an adequate reflection of in vivo
events. For example, measurements of Uro-D were done with diluted cytoplasmic
extract; and iron, which may have been reversibly inhibitory in vivo, could have been
diluted and no longer active in vitro. Also, concentrations ofcytochrome P-450 and
MDA may not indicate actual rates of hepatic microsomal heme synthesis or
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FIG. 8. Content of Malonyldialdehyde, a Product of Lipid Peroxidation in Homogenates of Livers from Rats
Treated withAllylisopropylacetamide(AIA) and FerrncCitrate. FemaleSprague-Dawley rats(I125-150g) werefasted for
24 h and then given AIA (400 mg/kg SC), ferrnc citrate(700 mg/kg, po) orthecombination. They were killed 17 h later.
Livers were perfused exhaustively with cold 0.15 M KCI and a 25% homogenate of pooled livers of five animals was
prepared. Portions of these homogenates were assayed for malonyldialdehyde by the method of Ottolenghi [78].
catabolism since both P-450 and MDA were being formed and degraded continu-
ously. Because of these problems, we have recently undertaken the study ofhepatic
heme synthesis and degradation in intact rats in vivo (see below).
2. Iron may inhibit some other step in heme biosynthesis besides Uro-D. Studies
of the overall rate of heme synthesis from ALA in vivo should uncover such a block
also.
3. Finally, iron may potentiate the drug-mediated induction of ALA synthetase
by a mechanism unrelated to the regulatory heme pool or heme biosynthesis. The
effect could' even be extra-hepatic, although our preliminary studies with chick
embryo liver cells in culture do suggest an iron effect in these isolated hepatocytes.
Perhaps, therefore, iron administration has an effect on ALA synthetase transcrip-
tion or translation not mediated by regulatory heme, as suggested in Fig. 6, Site 2.
Such an effect would be analogous to the effect ofiron onstimulation ofapo-ferritin
synthesis [85].
Comments on the Hypothesis that Iron and Other Metals Act as Physiological
Regulators ofHepatic Heme Metabolism
It has recently been proposed that iron itself rather than the iron-protoporphyrin
chelate is the "proximate" physiological regulator of heme metabolism [86]. In this
view, the chelation of iron by protoporphyrin as Fe-heme is considered an efficient
means for getting iron across various membranes. The effects of heme on ALA
synthetase and heme oxygenase activities ire envisioned to be due to the iron itself,
not the protoporphyrin chelate of iron.
Much ofthe evidence offered in support ofthissuggestion has been obtained from
studies, primarily carried out in rats, on effects of divalent cobalt on heme metabo-
lism. Certain other divalent metallic ions (Zn, Ni, Cu, Pt, Cd, Hg, Pb, Mn) and Fe+2
and Fe+3 have also been used, albeit less extensively t34,87]. It is suggested that
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effects of cobalt and other non-ferrous metals are due to the same mechanism as for
iron.
Administration of CoCl2 to intact rats [88-90] or to chick embryo liver cells in
culture [91] is followed by a rapid decrease in ALA synthetase activity. This has been
interpreted to be due principally to a direct repression bythe metal ofthe synthesis of
the enzyme [86]. However, others ave recently shown that the decrease in ALA
synthetase activity is probably due to the protoporphyrin chelate of cobalt (Co-
protoporphyrin) and not the metal itself [88a,88b]. The decrease may well be due to
inhibition of activity as well as inhibition of synthesis [89]. These data, by analogy,
support the more traditional view that heme or Fe-protoporphyrin (like Co-
protoporphyrin), not "free" ionic iron, regulates the activity of ALA synthetase.
The proposal that administration of non-chelated ionic iron and cobalt act in the
same way on ALA synthetase raises other problems since ferric citrate administration
potentiates the drug-mediated induction of ALA synthetase (Fig. 5, [73,74]) during
the same interval in which cobalt administration leads to a decrease in induced
enzyme activity [88,89].
A second site of action ofheavy metals on heme metabolism is their ability, at high
toxic doses, to induce hepatic heme oxygenase [33,34,86,87,90,91]. It has been
proposed that all these metals act to produce this induction and to decrease activity
of ALA synthetase by similar mechanisms [86]. However, much lower doses of
CoCl2 * 6H20 are required to maximally inhibit ALAS (3 mg/kg) than to maximally
induce heme oxygenase (60 mg/kg) in adult [92] and fetal [92a] rats. Similar marked
differences in dose response have also been observed for cobalt in cultured chick
embryo hepatocytes [91] and for endotoxin in rats [35]. The response ofhepatocytes
to increase activity of heme oxygenase is associated with toxic (near LD50) doses of
metals and endotoxin, and it seems unlikely that this is a physiological regulatory
mechanism for heme degradation.
The mechanism underlying increase of heme oxygenase activity by metals,
endotoxin or heme itself is not understood. Some consider it due to induction by
heme itself in a "regulatory" pool derived from increased degradation ofcytochrome
P-450 [35] or from newly synthesized heme normally destined for cytochrome P-450
([93], see Fig. 2), whereas others believe the metals directly [86] or through
metalloporphyrins [93a] induce synthesis of heme oxygenase.
Further work suggesting iron as the key regulator ofheme metabolism has recently
been presented [94] using neonatal rats in which erythrocyte hemolysis may increase
the heme, and therefore iron, available to the liver. Normally, these neonates are
resistant to inducers of ALA synthetase. Following repeated injections of Na2
EDTA, however, a response of ALA synthetase induction to AIA administration
occurred. These data were interpreted as indicating that iron represses ALA
synthetase, but many other possibilities exist.
Two final considerations are worthy ofnote: 1. As mentioned above(Fig. 4), in
man, activity of hepatic ALA synthetase is directly correlated with liver iron
concentration, whereas the new hypothesis [86] would suggest the opposite. 2. If
excess hepatic iron repressed induction of ALA synthetase, iron might be useful as a
treatment for acute hepatic porphyrias. However, ferric citrate potentiation of ALA
synthetase induction in rats (Fig. 5) makes this theoretically risky. Also, an AIP
patient with a severe fatal attack has been described who also was found to have a
considerable degree of hepatic siderosis [95]. The excess iron was suggested to have
exacerbated ratherthan to have mitigated the biochemical and clinical abnormalities.
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DIET AND HORMONAL CONTROL OF HEPATIC ALA SYNTHETASE
The Glucose Effect in Experimental and Clinical Porphyria
An effect of diet on experimental porphyria was identified before the biochemical
basis for the porphyria had been discovered [96], when it was found that carbohy-
drate or protein could prevent AIA-induced porphyria in rats. Soon after the
discovery by Granick and Urata [44] that ALA synthetase was inducible by a
porphyrinogenic compound, it was shown that induction ofthis enzyme in mammal-
ian liver could be blunted or prevented by high dietary intake ofglucose[97] (see Fig.
9). The effect of glucose in diminishing induction of hepatic ALA synthetase
provided an explanation for its ability to prevent production of experimental
porphyria. It also provided a rationale for the observation, repeatedly made, that
fasted animals responded to AIA and other porphyrinogenic compounds with more
induction of the enzyme and overproduction of heme precursors thandid non-fasted
animals. A similar "glucose effect," in which glucose administration repressed the
synthesis of other enzymes, had previously been described in microorganisms
[98-100] and rat liver [101,102].
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FIG. 9. The glucose effect on induction of hepatic 8-aminolevulinic acid synthetase by allylisopropylacetamide.
Female Sprague-Dawley rats, weighing 125-175 g, werefasted 48-72 h prior to sacrifice. Some weregiven oral glucose at
two different dose levels as shown and 15-20 min later received 400 mg/kg allylisopropylacetamide subcutaneously.
Control rats received distilled water followed by the same dose of drug. Each point represents activity in pooled
homogenate from four rats. Reprinted by permission from [41].
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Shortly thereafter thesefindings inexperimental porphyria were put to clinical use;
Welland et al. [103], showed that ALA and PBG excretions were reciprocally related
to carbohydrate and/or protein intake in acute intermittent porphyria (AIP). These
observations have been confirmed repeatedly by others [104-106]. We have also
shown that glycerol in man [106] and glycerol and fructose in the rat [41] are as
potent as glucose itself. Others have recently demonstrated an effect of fructose in
man also [109].
A glucose effect in clinical states of porphyrin overproduction is not limited to
AIP: it has also been demonstrated in variegate porphyria [107] and in protopor-
phyria [108]. Therefore, a high intake of glucose is a cornerstone of therapy,
particularly in the hereditary hepatic porphyrias [37,38]. It is often assumed that a
glucose effect does not occur in the erythropoietic porphyrias. However, several
pieces of evidence suggest otherwise:
1. A high levulose (fructose) intake was followed by increased erythrocyte
uroporphyrinogen synthetase and decarboxylase activities in hemolysates from AIP
patients, activities suggesting a possible carbohydrate effect onthe erythroid appara-
tus [109]. Unfortunately, this report did not include the duration of levulose therapy
and the daily IV dose purportedly given (372 mol or 67 kg) seems impossibly high.
Nor was it clear whether the sugar was being administered at the time that bloods
were drawn for the enzyme assays and whether levulose directly activated these
enzymes. Unless therapy had been prolonged (1-3 weeks) prior to assay, any
measured increases in hemolysate enzyme activities presumably would be due to
activation of enzymes already present in circulating erythrocytes. The only alterna-
tive possibility is that the treatment somehow stimulated release of young erythro-
cytes and reticulocytes into the peripheral circulation, cells known to have higher
activities of uroporphyrinogen synthetase.
In this same paper [109], peripheral blood leukocyte ALA synthetase was signifi-
cantly decreased (-35 to -72%, p < 0.001) following levulose therapy, further
suggesting that a glucose effect may occur in the bone marrow in human porphyria.
2. As mentioned above, a high carbohydrate intake has been found to decrease
fecal protoporphyrin excretion in protoporphyria [108]. The mechanism for this
effect is unknown, and may not be due to alterations in the rate of protoporphyrin
production per se, but rather to alterations in its secretion into bile or of its entero-
hepatic circulation. Furthermore, developing erythrocytes may not bethe sole source
of the excess protoporphyrin in this disease [110], although two research groups
[111,112] have recently made this proposal. Since decreased activity of heme
synthetase has been found in homogenates ofliver and cultured skinfibroblasts[28],
as well as in erythroblasts [29], from patients with protoporphyria, the possibility of
extra-erythrocytic sources of protoporphyrin production in this disease cannot yet be
discarded entirely. Despite these lingering uncertainties, the existence of a glucose
effect in protoporphyria raises the possibilitythat glucose can repress overproduction
of heme precursors in the bone marrow as well as in the liver.
3. As mentioned before, intravenous hemeinfusions decrease porphyrin overpro-
duction in congenital erythropoietic porphyria [58], a disease in which the bone
marrow is acknowledged to be the source ofsuch overproduction. It is therefore clear
that at least one repressor of ALA synthetase (heme) can act both intheliver and the
bone marrow in human porphyrias, and it suggests that others (carbohydrates) may
do the same.
Unfortunately, the glucose effect is not uniform in all the animals of any one
experiment (Bonkowsky, HL, unpublished observations) or in patients [56,105,106],
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for unknown reasons. Patients who have failed to respond biochemically to high
carbohydrate intakes have responded to heme infusions [56,59], indicating that heme
should be used in those patients who fail to respond sstisfactorily to more conserva-
tive therapy.
Biochemical Basisfor the Glucose Effect
In microorganisms, the earlier hypothesis of "catabolite repression" [100] as the
explanation for the glucose effect has given way to the well-supported conclusion that
this effect is mediated by 3'5'-cyclic-AMP (cAMP) [113,114]. Glucose inhibits the
synthesis of cAMP in E. coli with a resultant decrease ofintracellular concentrations
to one-tenth of that which occurs in the absence of glucose. cAMP, by binding to a
specific protein called "CAP," enhances transcription of many (but not all) bacterial
genes [113], including those subject to the glucose effect. Thus glucose acts to
decrease transcription by decreasing cAMP concentrations. Interestingly, this ap-
pears to be an effect mediated by glucose itself, not a metabolite.
In rat liver, several enzymes induced by cAMP (tyrosine aminotransferase, serine
dehydrase, and phosphoenolpyruvate carboxykinase) are repressed by glucose
feeding, which suggested that the glucose effect was mediated by cAMP in mammals
as well as in bacteria. However, this notion has proved not to be correct [113,115].
With respect to cAMP and hepatic ALA synthetase, we found that even large
doses of cAMP (400 mg/kg) or dibutyryl cAMP (200 mg/kg), given 7 and 3 h before
sacrifice decreased enzyme activity by 20-34 percent, rather than inducing it [41].
These compounds also decreased activity after AIA treatment (400 mg AIA/kg, 5 h
before sacrifice). These effects may be due to enzyme inhibition since both com-
pounds inhibited the formation of ALA as shown in Table 2.
Theophylline, an inhibitor of the phosphodiesterase which hydrolyzes cAMP,
decreased ALA synthetase activity when given alone or with dibutyryl cAMP, the
combination acting in an additive fashion [41]. Dibutyryl cAMP did not materially
influence the glucose effect on ALA synthetase[41]. The findings of others in intact
rats [116,117] were similar to ours just described.
However, in suspensions of isolated rat liver cells, dibutyryl cAMP (50 , M) or
AIA (1.2 mM), while producing no induction alone, together led to a 4-5 fold
increase of ALA synthetase activity after 6 h of exposure [118]. In this system, the
cyclic nucleotide thus appears to exert a "permissive effect" on enzyme induction,
similar to that described in vivo for hydrocortisone [1 19]. A similar role for cAMP
has recently been described in chick embryo liver cells in culture [120]. It is also of
TABLE 2
Inhibition of Rat Liver ALA Synthetase by Cyclic AMP
Final Concn. Relative Activity
Cyclic Nucleotide (mM) (N)
None 0 100
Cyclic AMP 5 71
0.1 78
0.01 79
N6, 02'-dibutyryl 5 43
Cyclic AMP 0.1 86
Assays were performed by the method of Marver et al. [127] on homogenate of the pooled livers of ten 48 h fasted
female Sprague-Dawley rats (100-lSOg), given AIA (400 mg/kg SC) 18 h before sacrifice. Control activity of ALA
synthetase was 630 nmol ALA/g liver/h.
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interest that glucose did not prevent induction produced by AIA and dibutyryl
cAMP in isolated rat liver cells [118], a finding which parallels Granick's earlier
failure to observe a glucose effect on the enzyme in isolated chick embryo liver cells
[43].
In contrast, a modest glucose effect(25-30 percent lowering ofinduction) has been
described in 17-day-old chick embryo liver in ovo, and in this system, unlike the rat,
dibutyryl cAMP enhanced by 10-15 percent the AIA-mediated induction of ALA
synthetase [121]. As in the rat, however, theophylline markedly repressed the
induction of chick embryo enzyme mediated by AIA, phenobarbital, and steroids
[122]. This inhibitory effect in the chick embryo could not be reversed by administra-
tion of dibutyryl cAMP [121].
In summary, current evidence favors the following conclusions:
1. cAMP is not a primary inducer of hepatic ALA synthetase, as it is for several
other enzymes which, like ALA synthetase, are repressed by glucose.
2. The glucose effect in rat liver, for all enzymes studied, is not mediated by a
lowering of cAMP levels.
Therefore, other explanations of the glucose effect must be sought. We did several
experiments to study this problem further [41]. First we tested the hypothesis that it
was not glucoseper se but some metabolite of glucose which mediated the effect. We
administered large doses of several carbohydrates, fatty acids, and acidic glycolytic
and TCA cycle intermediates to rats who also received AIA to induce ALA
synthetase. To our surprise, we found that glucose or those carbohydrates which are
efficiently converted to hepatic glucose (fructose, glycerol) were most effective,
repressing induction of the enzyme by 50-90 percent. Furthermore, 2-deoxyglucose,
a potent inhibitor of glucose-6-phosphate isomerase and thus of glycolysis did not
prevent the glucose effect. A role for glycogen deposition, previously suggested as a
possible mediator of the glucose effect [123], was not supported since diazoxide, a
potent glycogenolytic agent, did not prevent carbohydrate repression.
These results suggested that glucose, glucose-6-phosphate, or perhaps an interme-
diate in the hexose monophosphate shunt (HMPS) or uronic acid pathway were
candidates as mediators of the glucose effect on rat hepatic ALA synthetase. This
conclusion is also supported by the recent finding that uridine diphosphate glucose
feeding decreased enzyme induction [124].
Hormonal Influences on ALA Synthetase
Furthermore, we found no evidence for mediation of the glucose effect by
hormonal changes induced by glucose feeding. For example, although insulin
secretion is enhanced by glucose feeding in rats, insulin injections did not inhibit
ALA synthetase induction, and insulin lack, produced by prior alloxan administra-
tion, did not lead to enhanced but rather to decreased enzyme induction [41]. Some
liver enzymes susceptible to a glucose effect are induced by glucocorticoids and this
hormonal action is blocked by glucose feeding [113]. In the case of ALA synthetase,
this does not occur. Although, as mentioned above, glucocorticoids are required for
induction to occur [119], in large doses they do not induce the enzyme nor enhance
induction by AIA [41].
Available data therefore suggest that glucose itself, glucose-6-phosphate, or a distal
metabolite of glucose in the HMPS pathway, but not in the glycolytic pathway,
mediates the glucose effect on ALA synthetase. Despite numerous studies, however,
the precise mechanism of this fascinating and clinically important effect is yet to be
established.
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CONCLUSION
There have been many recent advances in our understanding of hepatic heme
metabolism and its control, but we still have much to learn. This area of research
therefore remains important to biochemists, to clinicians caring for patients with
disorders of porphyrin metabolism, and to clinical investigators seeking to provide a
bridge between basic and clinical disciplines for the mutual benefit of both and
especially for the eventual benefit of generations of patients yet unborn.
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